AMY BRIGHT: Open Payments
NPI 1215407267 · GOLDEN, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$831 in 27 payments from 11 companies in 2025. Trend: 2023 $443 · 2024 $881 · 2025 $831
Food & beverage: $831
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $143 |
| Edwards Lifesciences Corporation | 1 | $126 |
| Alnylam Pharmaceuticals Inc. | 5 | $115 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
| Medtronic, Inc. | 1 | $108 |
| AstraZeneca Pharmaceuticals LP | 3 | $63 |
| Biosense Webster, Inc. | 1 | $40 |
| BridgeBio Pharma, Inc. | 1 | $34 |
| PFIZER INC. | 2 | $34 |
| W. L. Gore & Associates, Inc. | 1 | $29 |
Products named: LEQVIO, AMVUTTRA, LINQ II, ELIQUIS, CAMZYOS, FARXIGA, CARTO 3, Attruby.
Industry payments across CO — which companies pay providers there.
